

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/508,251	04/10/2000	NAOSHI FUKUSHIMA	065678/0101	9585	
7:	590 05/21/2002				
STEPHEN B MAEBIUS			EXAMINER		
	T NW SUITE 500		HELMS, LARR	HELMS, LARRY RONALD	
WASHINGTON HARBOUR WASHINGTON, DC 20007-5109			ART UNIT	PAPER NUMBER	
			1642	111	
			DATE MAILED: 05/21/2002	14	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
Advisory Action	09/508,251	FUKUSHIMA ET AL.
Advisory Action	Examiner	Art Unit
	Larry R. Helms	1642
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence address
THE REPLY FILED 07 May 2002 FAILS TO PLACE THIS Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applica a timely filed amendment which	ition. A proper reply to a
	EPLY [check either a) or b)]	
<ul> <li>a)  The period for reply expires 3 months from the mailing date</li> <li>b)  The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).</li> </ul>	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing	date of the final rejection.
Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Offic timely filed, may reduce any earned patent term adjustment. See 37 C	If extension and the corresponding amo the shortened statutory period for reply be later than three months after the mail	unt of the fee. The appropriate extension originally set in the final Office action; or
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFF		
$2. \boxtimes$ The proposed amendment(s) will not be entered be	ecause:	
(a) X they raise new issues that would require further	er consideration and/or search (s	see NOTE below);
(b) $oxed{\boxtimes}$ they raise the issue of new matter (see Note b	elow);	
<ul><li>(c)  they are not deemed to place the application ir issues for appeal; and/or</li></ul>	n better form for appeal by mate	rially reducing or simplifying the
(d) they present additional claims without cancelling	ng a corresponding number of fi	nally rejected claims.
NOTE: <u>See Continuation Sheet</u> .		
3. Applicant's reply has overcome the following rejection	on(s): <u>none</u> .	
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	parate, timely filed amendment
5. ☑ The a) ☐ affidavit, b) ☐ exhibit, or c) ☑ request for application in condition for allowance because: see	reconsideration has been consideration has been consideration has been consideration.	dered but does NOT place the
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY to	o issues which were newly
7. For purposes of Appeal, the proposed amendments explanation of how the new or amended claims we		
The status of the claim(s) is (or will be) as follows:		
Claim(s) allowed: none.		
Claim(s) objected to: none.		
Claim(s) rejected: <u>13-23</u> .		
Claim(s) withdrawn from consideration:		
8. The proposed drawing correction filed on is a	a)∏ approved or b)∏ disappı	roved by the Examiner.
9. Note the attached Information Disclosure Statemen	it(s)( PTO-1449) Paper No(s)	
10. Other:	SHEELA H	UFF O UVA AMINER

U.S. Patent and Trademark Office

Continuation of 2. NOTE: the amendment fixed 5/7/02 amended claim 13to recite "said monocional antibody is other than 1F7". Support for the limitation is said to be at page 4, lines 6-11 and at page 5, lines 20-25, however, at the recited pages there is no mention of the 1F7 antibody let alone the limitations of "monoclonal antibody other than 1F7".